<DOC>
	<DOCNO>NCT02985281</DOCNO>
	<brief_summary>Evaluation Safety Efficacy Gratisovir ( Sofosbuvir ) - Ribavirin Therapy Egyptian Pediatric Patients With Chronic Hepatitis C Infection age 10- 18 year old .</brief_summary>
	<brief_title>Safety Efficacy Gratisovir ( Sofosbuvir ) - Ribavirin Therapy Pediatric Patients</brief_title>
	<detailed_description>Male female child ≥ 10 year ≤ 18 year age chronically infect hepatitis C virus , willing able complete study visit procedure . Acceptance parent recruit give verbal write informed consent . Patient childs Pugh class B C , compensate cirrhosis may enrol . Patient cirrhosis alpha fetoprotein 100 ng/ml patient coinfection Hepatitis B virus HIV exclude . Participation study procedure anticipate last 40 week include screen eligibility assessment phase ( 4 week duration ) , 24- week treatment phase , 12- week post treatment follow phase . A detailed treatment log return investigational product establish investigator ( pharmacist ) countersign investigator monitoring team . Compliance assess count number return tablet visit . A discontinuation defined period least seven consecutive day without study drug intake . Safety efficacy compare cirrhotic versus non-cirrhotic subject multivariate model test impact pretreatment characteristic safety , tolerability efficacy endpoint . Safety analysis : clinical adverse event display body system ( soc ) study subject treatment group , use MedDRA coding . Summary statistic safety efficacy endpoint display stratification parameter .</detailed_description>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Male female child ≥ 10 year ≤ 18 year age chronically infect hepatitis C virus . willing able complete study visit procedure . Acceptance parent recruit give verbal write informed consent . Patient child , Pugh class B C , compensate cirrhosis may enrol . 1 . Patient cirrhosis alpha fetoprotein 100 ng/ml . 2 . Patient coinfection hepatitis B virus Human Immunodeficiency Virus exclude . 3 . Creatinine clearance &lt; 50 ml/minute . 4 . Albumin &lt; 3 gm/dl . 5. aspartate aminotransferase alanine aminotransferase &gt; 10 upper limit normal . 6 . Pregnant lactating female . 7 . Associated morbidity uncontrolled diabetes mellitus , schistosomiasis .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>direct act antiviral drug , chronic hepatitis C virus infection</keyword>
</DOC>